Logo for Diagonal Bio

Diagonal Bio Investor Relations Material

Latest events

Logo for Diagonal Bio

Q1 2024

31 May, 2024
Logo for Diagonal Bio

Q4 2023

28 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Diagonal Bio

Access all reports
Diagonal Bio AB operates as a biotechnology company in Sweden. The company is focused on the development of drug candidate for treatment of diabetes and obesity, based on its technology for targeting the GLP-1 receptor. The company also develops small molecules for pharmaceutical and diagnostic purposes. It offers DiabNext, which is in Phase II trial for dibenzo-p-dioxin (DCDX)-induced significant reduction in pulmonary hypertension syndrome (PH). The company is based in Lund, Sweden.